

*AMENDMENTS TO THE SPECIFICATION*

Please replace the paragraph on page 16, lines 3-8, with the following paragraph:

***~~Figure 1~~ Figures 1A-1B***

Northern analysis of the novel estrogen receptor (ER $\beta$ ). Two different multiple tissue Northern blots (Clontech) (Figures 1A and 1B) were ~~hybridised~~ hybridized with a specific probe for ER $\beta$  (see examples). Indicated are the human tissues from which the RNA originated ~~from~~ and the position of the size markers in kilobases (kb).

Please replace the paragraph on page 17, lines 14-23, with the following paragraph:

***Figure 5 Figures 5A-C***

Transactivation assay using stably transfected CHO cell lines expressing ER $\alpha$  or ER $\beta$  together with the rat oxytocin-luciferase estrogen responsive reporter (see examples for details). Hormone-dependent transactivation curves were determined for 17 $\beta$  estradiol (Figure 5A) and for Org4094 (Figure 5B). For the ER antagonist raloxifen (Figure 5C), cells were treated with  $3 \times 10^{-10}$  mol/L 17 $\beta$ -estradiol together with increasing concentrations of raloxifen. Maximal values of the responses were arbitrarily set at 100%.

Please replace the paragraph on page 28, lines 13-22, with the following paragraph:

Transactivation studies performed on stably transfected ER $\alpha$  and ER $\beta$  cell lines gave similar absolute luciferase values. The curves for 17 $\beta$ -estradiol are very similar and show that half-maximal transactivation is reached with lower concentrations of hormone on ER $\alpha$  as compared to ER $\beta$  (Figure 5) (Figures 5A-5C). For Org4094 this is also the case, however, the effect observed is much more pronounced. The curves for raloxifen show that the potency of this antagonist to block transactivation on ER $\alpha$  is greater compared to its potency to block ER $\beta$  transactivation.

Application Serial No. 08/826,361  
Amendment Pursuant to §1.312 dated 01 October 2003


#### REMARKS

Applicants note for the record that the title of the invention was changed in the Examiner's Amendment (see Paper No. 37) to – DNA ENCODING NOVEL ESTROGEN RECEPTOR – although the Notice of Allowance submitted herewith reflects the original title.

The specification has been amended to conform the descriptions of Figures 1 and 5, at pages 16 and 17, respectively, with the replacement drawings submitted herewith.

Amendment has likewise been made to the specification at page 28 with respect to the modifications of Figure 5.

The above amendments do not constitute new matter, and their entry is therefore requested.

RESPECTFULLY SUBMITTED,					
<i>Name and Reg. Number</i>	Jeffrey L. Ihnen, Registration No. 28,957				
<i>Signature</i>				<i>Date</i>	01 October 2003
<i>Address</i>	Rothwell, Figg, Ernst & Manbeck 1425 K Street, N.W., Suite 800				
<i>City</i>	Washington	<i>State</i>	D.C.	<i>Zip Code</i>	20005
<i>Country</i>	U.S.A.	<i>Telephone</i>	202-783-6040	<i>Fax</i>	202-783-6031